Difference between revisions of "Afatinib (Gilotrif)"
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: | + | Class/mechanism: Irreversible tyrosine kinase inhibitor of members of the erbB family, such as EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2)<ref>[http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2011/sept_06_2011.html Press release: Boehringer Ingelheim broadens its breast cancer clinical trial program for the investigational compound afatinib]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 21:54, 21 February 2012
Also known as Tomtovok. In clinical trials
General information
Class/mechanism: Irreversible tyrosine kinase inhibitor of members of the erbB family, such as EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2)[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.